What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
Pierre Fenaux spends much of his time researching Internal medicine, Leukemia, Surgery, Gastroenterology and Myeloid leukemia.
Pierre Fenaux interconnects Immunology and Oncology in the investigation of issues within Internal medicine.
His research integrates issues of Myeloid, Etoposide, Mitoxantrone and Chronic myelomonocytic leukemia in his study of Leukemia.
His work in Gastroenterology addresses subjects such as Placebo, which are connected to disciplines such as Clinical endpoint.
The Myeloid leukemia study combines topics in areas such as Molecular biology, CEBPA, Bone marrow and Point mutation.
His studies in Myelodysplastic syndromes integrate themes in fields like Azacitidine, Clinical trial, Anemia and Lenalidomide.
His most cited work include:
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. (2438 citations)
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel (2002 citations)
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study (1802 citations)
What are the main themes of his work throughout his whole career to date?
Pierre Fenaux mostly deals with Internal medicine, Myelodysplastic syndromes, Oncology, Gastroenterology and Surgery.
His work carried out in the field of Internal medicine brings together such families of science as Azacitidine and Immunology.
His study in Myelodysplastic syndromes is interdisciplinary in nature, drawing from both Lower risk, Myeloid leukemia and Anemia.
His work deals with themes such as Clinical trial and Transplantation, which intersect with Oncology.
His Gastroenterology study combines topics in areas such as Chemotherapy regimen, Phases of clinical research, Neutropenia, Pediatrics and Bone marrow.
His Chemotherapy research incorporates themes from Acute promyelocytic leukemia and Incidence.
He most often published in these fields:
- Internal medicine (63.86%)
- Myelodysplastic syndromes (33.79%)
- Oncology (25.22%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (63.86%)
- Myelodysplastic syndromes (33.79%)
- Oncology (25.22%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Myelodysplastic syndromes, Oncology, In patient and Myeloid leukemia.
His research in Internal medicine intersects with topics in Gastroenterology and Azacitidine.
His Gastroenterology research is multidisciplinary, relying on both Vasculitis and Chronic myelomonocytic leukemia.
His Myelodysplastic syndromes study integrates concerns from other disciplines, such as Clinical trial, MEDLINE, Adverse effect, Anemia and Placebo.
The study incorporates disciplines such as Hematopoietic stem cell transplantation, Phases of clinical research, Cytarabine, Decitabine and Bone marrow in addition to Oncology.
His Myeloid leukemia research focuses on Refractory and how it connects with Survival analysis.
Between 2017 and 2021, his most popular works were:
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia (184 citations)
- Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (85 citations)
- Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (85 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
His primary scientific interests are in Internal medicine, Myelodysplastic syndromes, Oncology, Azacitidine and Myeloid leukemia.
Internal medicine is closely attributed to Gastroenterology in his research.
His study in the field of International Prognostic Scoring System is also linked to topics like In patient.
His Oncology research is multidisciplinary, incorporating elements of Phases of clinical research, Cytarabine, Survival rate, Venetoclax and Complete remission.
His Azacitidine study also includes fields such as
- Cancer research most often made with reference to Febrile neutropenia,
- Mutant together with Leukopenia.
His Myeloid leukemia research is multidisciplinary, incorporating perspectives in IDASANUTLIN and Refractory.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
